Growth inhibition, cytokinesis failure and apoptosis of multidrug-resistant leukemia cells after treatment with P-glycoprotein inhibitory agents

Leukemia

Volumn 13, Issue 5, 1999, Pages 768-778

  Lehne, G ^b   De Angelis, P ^c   Den Boer, M ^a   Rugstad, H E ^c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c NONE

Author keywords

Apoptosis; Leukemia; P glycoprotein; Resistance modulater

Indexed keywords

CYCLOSPORIN; CYTOKINE; GLYCOPROTEIN P; PROTEIN INHIBITOR; VALSPODAR;

APOPTOSIS; ARTICLE; CELL GROWTH; CELL STRAIN HL 60; CELL STRAIN K 562; CELL TRANSPORT; CYTOKINESIS; CYTOTOXICITY; DRUG RESPONSE; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL LINE; PRIORITY JOURNAL;

EID: 0032980591     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401392     Document Type: Article

References (75)

1. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976; 455: 152-162.
2. Pastan I, Gottesman M. Multiple-drug resistance in human cancer. New Engl J Med 1987; 316: 1388-1393.
3. Marie IP, Zittoun R, Sikic BI. Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 1991; 78: 586-592.
4. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992; 79: 473-476.
5. Yuen AR, Sikic BI. Multidrug resistance in lymphomas. J Clin Oncol 1994; 12: 2453-2459.
6. Chan HS, Thorner PS, Haddad G, Ling V. Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 1990; 8: 689-704.
7. Chan HS, Haddad G, Thorner PS, DeBoer C, Lin YP, Ondrusek N, Yeger H, Ling V. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. New Engl J Med 1991; 325: 1608-1614.
8. Baldini N, Scotlandi K, Barbanti-Brodano C, Manara MC, Maurici D, Bacci G, Bertoni F, Picci P, Sottili S, Campanacci M et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. New Engl J Med 1995; 333: 1380-1385.
9. Ford JM. Modulators of multidrug resistance. Preclinical studies. Hematol Oncol Clin North Am 1995; 9: 337-361.
10. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981; 41: 1967-1972.
11. Candell J, Valle V, Soler M, Rius J. Acute intoxication with verapamil. Chest 1979; 75: 200-201.
12. Twentyman PR, Bleehen NM. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin. Eur J Cancer 1991; 27: 1639-1642.
13. Loor F, Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Emmer G. SDZ 280-446, a novel semi-synthetic cyclopeptolide: in vitro and in vivo circumvention of the P-glycoprotein-mediated tumour cell multidrug resistance. Br J Cancer 1992; 65: 11-18.
14. Starling JJ, Shepard RL, Cao J, Law KL, Norman BH, Kroin JS, Ehlhardt WJ, Baughman TM, Winter MA, Bell MG, Shih C, Gruber J, Elmquist WF, Dantzig AH. Pharmacological characterization of LY335979: a potent cyclopropyldibenzosuberane modulator of P-glycoprotein. Adv Enzyme Regul 1997; 37: 335-347.
15. Dantzig AH, Shepard RL, Cao J, Law KL, Ehlhardt WJ, Baughman TM, Bumol TF, Starling JJ. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 1996; 56: 4171-4179.
16. Naito M, Watanabe T, Tsuge H, Koyama T, Oh-hara T, Tsuruo T. Potentiation of the reversal activity of SDZ PSC833 on multi-drug resistance by an anti-P-glycoprotein monoclonal antibody MRK-16. Int J Cancer 1996; 67: 435-440.
17. Tiberghien F, Loor F. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anticancer Drugs 1996; 7: 568-578.
18. Sonneveld P, Marie JP, Huisman C, Vekhoff A, Schoester M, Faussat AM, van Kapel J, Groenewegen A, Charnick S, Zittoun R, Lowenberg B. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. Leukemia 1996; 10: 1741-1750.
19. Boote DJ, Dennis IF, Twentyman PR, Osborne RJ, Laburte C, Hensel S, Smyth JF, Brampton MH, Bleehen NM. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 1996; 14: 610-618.
20. Kornblau SM, Estey E, Madden T, Tran HT, Zhao S, Consoli U, Snell V, Sanchez-Williams G, Kantarjian H, Keating M, Newman RA, Andreeff M. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J Clin Oncol 1997; 15: 1796-1802.
21. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 1989; 58: 137-171.
22. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Komano T, Hori R. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 1992; 267: 24248-2452.
23. Tatsuta T, Naito M, Oh-hara T, Sugawara I, Tsuruo T. Functional involvement of P-glycoprotein in blood-brain barrier. J Biol Chem 1992; 267: 20383-20391.
24. Drach J, Gsur A, Hamilton G, Zhao S, Angerler J, Fiegl M, Zojer N, Raderer M, Haberl I, Andreeff M, Huber H. Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes. Blood 1996; 88: 1747-1754.
25. Raghu G, Park SW, Roninson IB, Mechetner EB. Monoclonal antibodies against P-glycoprotein, an MDR1 gene product, inhibit interleukin-2 release from PHA-activated lymphocytes. Exp Hematol 1996; 24: 1258-1264.
26. Lehne G, Rugstad HE. Cytotoxic effect of the cyclosporin PSC 833 by inhibition of P-glycoprotein in multidrug resistant leukemia cells. Br J Cancer 1998; 78: 593-600.
27. Knowles BB, Howe CC, Aden DP. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 1980; 209; 497-499.
28. Collins SJ, Callo RC, Gallagher RE. Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature 1977; 270: 347-349.
29. Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1975; 45: 321-334.
30. Gruber A, Briese B, Arestrom I, Vitols S, Bjorkholm M, Peterson C. Effect of verapamil on daunorubicin accumulation in human leukemic cells with different levels of MDR1 gene expression. Leukemia Res 1993; 17: 353-358.
31. Lehne C, De Angelis P, Clausen OP, Egeland T, Tsuruo T, Rugstad HE. Binding diversity of antibodies against external and internal epitopes of the multidrug resistance gene product P-glycoprotein. Cytometry 1995; 20: 228-237.
32. Den Boer ML, Zwaan CM, Pieters R, Kazemier KM, Rottier MM, Flens MJ, Scheper RJ, Veerman AJ. Optimal immunocytochemical and flow cytometric detection of P-gp, MRP and LRP in childhood acute lymphoblastic leukemia. Leukemia 1997; 11: 1078-1085.
33. Lehne G, De Angelis P, Clausen OPF, Rugstad HE. Human hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines. Br J Cancer 1996; 74: 1719-1729.
34. Gorczyca W, Tuziak T, Kram A, Melamed MR, Darzynkiewicz Z. Detection of apoptosis-associated DNA strand breaks in fine-needle aspiration biopsies by in situ end labeling of fragmented DNA. Cytometry 1994; 15: 169-175.
35. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.
36. De Angelis P, Stokke T, Smedshammer L, Lothe RA, Lehne G, Chen Y, Clausen OP. P-glycoprotein is not expressed in a majority of colorectal carcinomas and is not regulated by mutant p53 in vivo. Br J Cancer 1995; 72: 307-311.
37. Young IT. Proof without prejudice: use of the Kolmogorov-Smirnov test for the analysis of histograms from flow systems and other sources. J Histochem Cytochem 1977; 25: 935-941.
38. Leith CP, Chen IM, Kopecky KJ, Appelbaum FR, Head DR, Godwin JE, Weick JK, Willman CL. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/efflux-cases. Blood 1995; 86: 2329-2342.
39. Scambia G, Panici PB, Contu G, De Vincenzo R, Ferrandina G, Isola G, Maccio A, Mancuso S. Mechanisms and modulation of resistance to anthracyclines. Int J Oncol 1994; 4: 951-959.
40. Stride BD, Grant CE, Loe DW, Hipfner DR, Cole SPC, Deeley RG. Pharmacological characterization of the murine and human orthologs of multidrug-resistance protein in transfected human embryonic kidney cells. Mol Pharmacol 1997; 52: 344-353.
41. Velculescu VE, El-Deiry WS. Biological and clinical importance of the p53 tumor suppressor gene. Clin Chem 1996; 42: 858-868.
42. Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449-1456.
43. Germann UA, Pastan I, Gottesman MM. P-glycoproteins: mediators of multidrug resistance. Semin Cell Biol 1993; 4: 63-76.
44. Krishnamachary N, Center MS. The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Res 1993; 53: 3658-3661.
45. Sahraoui Y, Allouche M, Ammar A, Spanakis E, Clemenceau C, Jasmin C, Perraki M, Varela-Millot C, Georgoulias V. Interleukin 2 production and interleukin 2 receptor expression by human immature leukemic T cells. Leukemia 1992; 6: 1025-1035.
46. Ghaderi AA, Richardson P, Cardona C, Millsum MJ, Ling N, Gillis S, Ledbetter J, Gordon J. Stimulation of B-chronic lymphocytic leukemia populations by recombinant interleukin-4 and other defined growth-promoting agents. Leukemia 1988; 2: 165-170.
47. Drexler HG, Zaborski M, Quentmeier H. Cytokine response profiles of human myeloid factor-dependent leukemia cell lines. Leukemia 1997; 11: 701-708.
48. Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, Sarfati M. Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med 1992; 176: 1319-1326.
49. Koeffler HP, Billing R, Lusis AJ, Sparkes R, Golde DW. An undifferentiated variant derived from the human acute myelogenous leukemia cell line (KC-1). Blood 1980; 56: 265-273.
50. Lozzio BB, Lozzio CB, Bamberger EC, Feliu AS. A multipotential leukemia cell line (K-562) of human origin. Proc Soc Exp Biol Med 1981; 166: 546-550.
51. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991; 66: 85-94.
52. Ferrari S, Grande A, Manfredini R, Tagliafico E, Zucchini P, Torelli C, Torelli U. Expression of interleukins 1, 3, 6, stem cell factor and their receptors in acute leukemia blast cells and in normal peripheral lymphocytes and monocytes. Eur J Haematol 1993; 50: 141-148.
53. Young DC, Wagner K, Griffin JD. Constitutive expression of the granulocyte-macrophage colony-stimulating factor gene in acute myeloblastic leukemia. J Clin Invest 1987; 79: 100-106.
54. Bradbury D, Rogers S, Reilly IA, Kozlowski R, Russell NH. Role of autocrine and paracrine production of granulocyte-macrophage colony-stimulating factor and interleukin-1 beta in the autonomous growth of acute myeloblastic leukaemia cells - studies using purified CD34-positive cells. Leukemia 1992; 6: 562-566.
55. Zhu YM, Bradbury DA, Keith FJ, Russell N. Absence of retinoblastoma protein expression results in autocrine production of interleukin-6 and promotes the autonomous growth of acute myeloid leukemia blast cells. Leukemia 1994; 8: 1982-1988.
56. Lemoli RM, Fortuna A, Tafuri A, Fogli M, Amabile M, Grande A, Ricciardi MR, Petrucci MT, Bonsi L, Bagnara G, Visani G, Martinelli G, Ferrari S, Tura S. Interleukin-9 stimulates the proliferation of human myeloid leukemic cells. Blood 1996; 87: 3852-3859.
57. Kobayashi S, Teramura M, Sugawara I, Oshimi K, Mizoguchi H. Interleukin-11 acts as an autocrine growth factor for human megakaryoblastic cell lines. Blood 1993; 81: 889-893.
58. Williams GT, Smith CA, Spooncer E, Dexter TM, Taylor DR. Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature 1990; 343: 76-79.
59. Stam K, Heisterkamp N, Grosveld G, de Klein A, Verma RS, Coleman M, Dosik H, Groffen J. Evidence of a new chimeric ber/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome. New Engl J Med 1985; 313: 1429-1433.
60. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 1994; 83: 1179-1187.
61. Bedi A, Barber JP, Bedi GC, el-Deiry WS, Sidransky D, Vala MS, Akhtar AJ, Hilton J, Jones RJ. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood 1995; 86: 1148-1158.
62. Pallis M, Zhu YM, Russell NH. Bcl-x(L) is heterogenously expressed by acute myeloblastic leukaemia cells and is associated with autonomous growth in vitro and with P-glycoprotein expression. Leukemia 1997; 11: 945-949.
63. Bosanquet AG, Bell PB, Burlton AR, Amos TA. Correlation of bcl-2 with P-glycoprotein expression in chronic lymphocytic leukaemia and other haematological neoplasms but of neither marker with ex vivo chemosensitivity or patient survival. Leuk Lymphoma 1996; 24: 141-147.
64. Canman C, Kastan M. Role of p53 in apoptosis. Adv Pharmacol 1997; 41: 429-460.
65. Clave E, Carosella ED, Gluckman E, Dubray B, Socie G. Ionizing radiation effects on the KG1 a primitive hematopoietic cell line. Int J Radiat Oncol Biol Phys 1996; 35: 709-719.
66. Wolf D, Rotter V. Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc Natl Acad Sci USA 1985; 82: 790-794.
67. Law JC, Ritke MK, Yalowich JC, Leder GH, Ferrell RE. Mutational inactivation of the p53 gene in the human erythroid leukemic K562 cell line. Leukemia Res 1993; 17: 1045-1050.
68. Wang Y, Ramqvist T, Szekely L, Axelson H, Klein G, Wiman KG. Reconstitution of wild-type p53 expression triggers apoptosis in a p53-negative v-myc retrovirus-induced T-cell lymphoma line. Cell Growth Differ 1993; 4: 467-473.
69. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA, Lonning PE. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Med 1996; 2: 811-814.
70. Bech-Hansen NT, Till JE, Ling V. Pleiotropic phenotype of colchicine-resistant CHO cells: cross-resistance and collateral sensitivity. J Cell Physiol 1976; 88: 23-31.
71. Hill BT. Modulation of antitumour drug resistance: experimental laboratory data and results of clinical evaluation. Cancer Treat Rev 1990; 17: 197-202.
72. Callaghan R, Riordan JR. Collateral sensitivity of multidrug resistant cells to narcotic analgesics is due to effects on the plasma membrane. Biochim Biophys Acta 1995; 1236: 155-162.
73. Stow MW, Warr JR. Reduced influx is a factor in accounting for reduced vincristine accumulation in certain verapamil-hypersensitive multidrug-resistant CHO cell lines. FEBS Lett 1993; 320: 87-91.
74. Quesada AR, Barbacid MM, Mira E, Aracil M, Marquez G. Chemosensitization and drug accumulation assays as complementary methods for the screening of multidrug resistance reversal agents. Cancer Lett 1996; 99: 109-114.
75. Evers R, Kook M, van Deemter L, Janssen H, Calafat J, Oomen LC, Paulusma CC, Oude Elferink RP, Baas F, Schinkel AH, Borst P. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J Clin Invest 1998; 101: 1310-1319.